Integrated Management of Acute and Chronic Cardiovascular Disease

Transcription

1 13 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease ORGANIZERS: KURT HUBER (Austria) BERNARD GERSH (USA) HARALD DARIUS (Germany) OTMAR PACHINGER (Austria) The Spectrum from Prevention to Intervention under the auspices of MAIN TOPICS: Acute Coronary Syndromes Anticoagulants Antiplatelet Therapy Atrial Fibrillation Biomarkers Case Presentations Chronic Coronary Artery Disease Devices Diabetes Heart Failure Hyperlipidemia Hypertrophic Cardiomyopathy Imaging Interventional Cardiology NSTE-ACS Pulmonary Hypertension STEMI TAVI Innsbruck, Austria Austria Trend Congress Hotel January 29 31, 2012 PROGRAM

2 PREFACE This international meeting takes place for the 13th time in Austria (after Serfaus and Oberlech/Arlberg now for the 3rd time in the row in Innsbruck). It has been endorsed by the Working Groups of Thrombosis and Acute Cardiac Care of the European Society of Cardiology and by the Working Group of Atherosclerosis, Thrombosis and Vascular Biology (ATVB) of the Austrian Society of Cardiology (Österreichische Kardiologische Gesellschaft (ÖKG). More than 40 international and national experts will guarantee an interesting meeting of newest basic and clinical knowledge in acute coronary syndromes, atrial fibrillation and other cardiac diseases as well as pharmacotherapy and device therapy. Number of attendees is limited to allow interactions and discussions on cases and frontal presentations a rare situation in our world of mega-congresses. The organizers will also invite the best abtracts for moderated poster presentations and award the best-of basic and clinical posters with 3000 in total. Deadline for abstract submission is December 31, Please send your abstract (maximum 1 DIN A4 page) to Prof. Dr. Kurt Huber, 3rd Med. Dept., Cardiology and Emergency Medicine, Wilhelminenhospital, Montleart Strasse 37, A-1160 Vienna, Austria or per to kurt.huber@meduniwien.ac.at. A panel of blinded international experts will decide over acceptance for presentation. We hope to have raised your interest in participation in this outstanding meeting. With best regards Kurt Huber (for the organizers) Vienna, November 2011

3 GENERAL INFORMATION Scientific Program Organization Kurt Huber, MD, FESC, FACC Director, 3 rd Department of Medicine Cardiology & Emergency Medicine, Wilhelminenhospital Montleartstrasse 37, A-1160 Vienna, Austria Tel.: (+43/1) , Fax: (+43/1) kurt.huber@wienkav.at Congress Organization and Secretariat Congress and Study Concept GesmbH Widerhoferplatz 4/3/19, A-1090 Vienna, Austria Contact: Ms. Mag. Franziska Beckmann Tel./Fax: (+43/1) csconcept@chello.at Medical Exhibition and Advertising Medizinische Ausstellungs und Werbegesellschaft Freyung 6, A-1014 Vienna, Austria Contact: Ms. Sonja Chmella Tel.: (+43/1) , Fax: (+43/1) maw@media.co.at, Venue Austria Trend Hotel, Innsbruck Innrain A-6020 Innsbruck Tel.: (+43/512) Fax.: (+43/512) congress@austria-trend.at Congress Fees: 500. / 250. (reduced fee for physicians in education) 2-day attendance: 300. / day attendance: 150. /100. Internet-Information:

4 PROGRAM SCHEDULE Saturday, January 28, 2012 Arrivals 19:00 Welcome Cocktail 20:30 Get-Together-Evening Sunday, January 29, :40 Welcome (K. Huber, AT) 08:45-10:30 Symposium I: Heart failure and valves chairs: M. Böhm (DE), M. Grimm (AT) 08:45 Ischemic mitral regurgitation: The surgeons business (P. Kolh, BE) 09:10 Cases#1&2 TAVI uncomplicated and complicated procedures (J. Aichinger, AT) 09:25 Surgical approaches to the management of patients with CAD and LV Dysfunction. Lessons from STICH and the VAD (B. Gersh, US) 09:50 Cases#3&4 TAVI uncomplicated and complicated procedures (A. Geppert, AT) 10:05 More informations on TAVI (B. Windecker, CH) 10:30-11:00 Break, Exhibition 11:00-11:30 Main Lecture I: Pulmonary Hypertension moderator: B. Gersh (US) 11:00 Update 2012 (Irene Lang, AT) 11:30-13:10 Symposium II: STEMI chairs: K. Huber (AT), G. Stone (US) 11:30 Potential and pitfalls of regional STEMI networks (R. Welsh, CD) 11:55 Current indications for thrombolytic therapy in the primary PCI era (S. Halvorsen, NO) 12:20 Primary PCI: DES vs. BMS single vessel vs. multivessel PCI (W. Wijns, BE) 12:40 Cardiogenic shock: Current outcomes and future directions (H. Thiele, DE) 12:55 Stent for Life Initiative Implementation of primary PCI (S. Kristensen, DK)

5 PROGRAM SCHEDULE Sunday, January 29, :10-14:00 Lunch Break, Basic Research Posters (Moderation: J. Wojta, AT) 14:00-15:00 Special Symposium: Old and new antiplatelet agents (sponsored by Eli Lilly/Daiichi Sankyo) 15:00-16:40 Symposium III: Interventionional cardiology chairs: P. Kolh (BE), W. Wijns (BE) 15:00 PCI vs. CABG in multivessel disease (O. Pachinger, AT) 15:20 Case#5 Complicated LM stenting (D. Gulba, DE) 15:35 Left main intervention and bifurcations an update (G. Stone, US) 16:00 Case#6 Multiple stents in 3-VD (I. Lang, AT) 16:15 Impact of residual thrombus after primary PCI for STEMI (F. Van de Werf, BE) 16:40-17:00 Break, Exhibition 17:00-18:50 Symposium IV: Risk factors chairs: J. Bax (NL), B. Pieske (AT) 17:00 ESC guidelines: Treatment of dyslipidemia are we missing something? (R. De Caterina, IT) 17:20 Case#7 A patient with rare hyperlipidemia (C. Saely, AT) 17:35 Diabetes and atherosclerosis: Are the predictors the same in all arterial beds? (H. Drexel, AT) 17:55 Diabetes mellitus: What does the clinical cardiologist need to know? (T. Wascher, AT) 17:15 Case#8 Hyperglycemia in ACS (S. Farhan, AT) 18:30 Cellular risk factors for atherothrombosis (J. Wojta, AT) 20:00 Faculty Dinner

6 PROGRAM SCHEDULE Monday, January 30, :40-10:30 Symposium V: NSTE-ACS chairs: E. Swahn (SE), F.W.A. Verheugt (NL) 08:40 The new NSTEMI guidelines differences between Europe and North America? (S. Kristensen, DK) 09:00 Case#9 A patient with ACx occlusion (H. Alber, AT) 09:20 hs-troponin in ACS: clinical implications (C. Granger, US) 09:35 New biomarkers in ACS (C. Müller, CH) 09:50 Case#10 Echocardiography in the diagnosis of NSTEMI (H.-J. Nesser, AT) 10:05 The incremental role of imaging in acute ischemic syndromes (J. Bax, NL) 10:30-11:00 Break, Exhibition 11:00-11:30 Main Lecture I: Hypertrophic cardiomyopathy moderator: O. Pachinger (AT) 11:00 Management issues in HCM : Impact of the guidelines (B. Gersh, US) 11:30-13:10 Symposium VI: New developments in device therapy chairs: P. Clemmensen (DK), W. Wijns (BE) 11:30 Biodegradable vascular scaffolds (H. Schühlen, DE) 11:50 Renal plexus ablation (O. Pachinger, AT) 12:10 Mitraclip (H.-J. Nesser, AT) 12:30 Interventional strategies and hypothermia in comatose survivors of cardiac arrest (M. Noc, SI) 12:50 2 nd and 3 rd generation stents (S. Windecker) 13: Lunch Break, Clinical Research Posters I (Moderator: I. Lang, DE)

7 PROGRAM SCHEDULE Monday, January 30, :00-15:00 Satellite Symposium: Dabigatran for atrial fibrillation (sponsored by Boehringer Ingelheim) 15:00-16:30 Symposium VII: Chronic CAD and miscellaneous chairs: T. Lüscher (CH), P. Kolh (BE) 15:00 Ranolazine (B. Pieske, AT) 15:20 Case#11 Recurrent pericarditis (M. Frick, AT) 15:35 Ivabradine (M. Böhm, DE) 15:55 Case#12 Cardiac Amyloidosis (G. Jakl, AT) 16:10 Is chronic CAD really stable? Things may not be what they seem (B. Gersh, US) 16:30-17:00 Break, Exhibition 17:00-18:30 Symposium VIII: Arrhythmias chairs: R. Welsh (CDN), M. Borggrefe (DE) 17:00 Case#13 Ischemic stroke in a patient with atrial fibrillation under aspirin (T. Höchtl, AT) 17:15 Stroke prevention in atrial fibrillation: A changing landscape (C. Granger, US) 17:45 Case#14 ICD-induced complications (G. Jakl, AT) 18:00 Critical issues in the management of arrhythmias: ablation, drugs, CRT (M. Borggrefe, DE) 20:00 Social Evening

8 PROGRAM SCHEDULE Tuesday, January 31, :40-10:30 Symposium IX: Antithrombotic strategies in ACS co-organized by the WG on Thrombosis of the ESC chairs: D. Gulba (DE), S. Kristensen (DK) 08:40 Bivalirudin in high-risk patients (U. Zeymer, DE) 09:00 Factor Xa-inhibitors (C. Granger, US) 09:25 Antiplatelet agents (H. Darius, DE) 09:50 Triple therapy and bridging to surgery (F.W.A. Verheugt, NL) 10:10 Reasons not to follow the new ACS guidelines in all patients: Experiences from a high-frequency interventional center (M. Noc, SI) 10:30-11:00 Break, Exhibition 11:00-11:30 Main Lecture III: History of ACS Therapy moderator: D. Milicic (CR) 11:00 ACS from Eisenhower s heart attack to modern concepts (T. Lüscher, CH) 11:30-12:30 Special Symposium: Factor Xa-Inhibition New Indications (sponsored by Bayer Austria) 12:30-13:30 Lunch Break, Clinical Research Posters II (Moderation: U. Zeymer, DE) 13:30-15:00 Symposium X: Case-based discussions in ACS co-organized by the WG on Acute Cardiac Care of the ESC chairs: U. Zeymer (DE), R. DE Caterina (IT) 13:30 case#15 The patient with chest pain presenting at home or at work (K. Huber, AT) 14:00 case#16 The patient with chest pain entering the emergency department (C. Müller, CH) 14:30 case#17 The patient with acute chest pain and ECG changes suspect for severe three vessel or left main disease (P. Clemmensen, NL)

9 PROGRAM SCHEDULE Tuesday, January 31, :00-15:15 Coffee Break 15:15-00:00 Main Lecture IV: Future of ACS Therapy moderator: F. Van de Werf (BE) 15:15 Innovation, investigation and implementation of new management in ACS (E. Swahn, SE) 16:45-00:00 Poster Awards, Farewell moderation: K. Huber (AT), H. Darius (DE), B. Gersh (US), O. Pachinger (AT)

10 SATELLITE SYMPOSIA / SPECIAL SYMPOSIA Sunday, January 29, :00-15:00 Special Symposium: Old and new antiplatelet agents (sponsored by Eli Lilly/Daiichi Sankyo) chairs: D. Milicic (CR), S. Kristensen (DK) 14:00 IV vs. IC application of GPIs in STEMI referred for primary PCI (H. Thiele, DE) 14:20 Prasugrel Data from subgroup analyses (H. Schühlen, DE) 14:40 Which ADP receptor-blocker for which patient (K. Huber, AT) Monday, January 30, :00-15:00 Satellite Symposium: Dabigatran for atrial fibrillation (sponsored by Boehringer Ingelheim) chairs: S. Halvorsen (NO), D. Gulba (DE) 14:00 Epidemiology and risk stratification in atrial fibrillation (H.-J. Nesser, AT) 14:20 RE-LY trial: Subgroup analyses (H. Darius, DE) 14:40 Practical implications: triple therapy, perioperative setting, bleeding (F.W.A. Verheugt, NL) Tuesday, January 31, :30-12:30 Special Symposium: Factor Xa-Inhibition New Indications (sponsored by Bayer Austria) moderation: I. Lang (AT) 11:30 Stroke Prevention (H.-J. Nesser, AT) 12:00 Acute Coronary Syndrome (K. Huber, AT)

11 SPONSORS (with ) ASTRAZENECA Austria GmbH, Vienna AstraZeneca BAYER Austria GmbH, Vienna BOEHRINGER INGELHEIM RCV GmbH & Co KG, Vienna B.R.A.H.M.S GmbH, Henningsdorf/Berlin, D IROKO Cardio International, Geneve, CH CORDIS, a Johnson & Johnson company, Vienna ELI LILLY/DAIICHI SANKYO, Vienna The MEDICINES Company MEDTRONIC Austria ST. JUDE Medical Medizintechnik GmbH, Vienna DEADLINE FOR ABSTRACTS December 31, 2011 (for more information see Preface)

12 FACULTY Josef AICHINGER (Austria) Hannes ALBER (Austria) Jeroen BAX (The Netherlands) Michael BÖHM (Germany) Martin BORGGREFE (Germany) Peter CLEMMENSEN (Denmark) Raffaele DE CATERINA (Italy) Harald DARIUS (Germany) Heinz DREXEL (Austria) Serdar FARHAN (Austria) Matthias FRICK (Austria) Alexander GEPPERT (Austria) Bernard GERSH (USA) Chris GRANGER (USA) Michael GRIMM (Austria) Dietrich GULBA (Germany) Sigrun HALVORSEN (Norway) Thomas HÖCHTL (Austria) Kurt HUBER (Austria) Gabriele JAKL (Austria) Philippe KOLH (Belgium) Steen KRISTENSEN (Denmark) Irene LANG (Austria) Thomas LÜSCHER (Switzerland) Davor MILICIC (Croatia) Christian MÜLLER (Switzerland) Hans-Joachim NESSER (Austria) Marko NOC (Slovenia) Otmar PACHINGER (Austria) Burkert PIESKE (Austria) Christoph SAELY (Austria) Helmut SCHÜHLEN (Germany) Gregg W. STONE (USA) Eva SWAHN (Sweden) Holger THIELE (Germany) Frans Van de WERF (Belgium) Freek VERHEUGT (The Netherlands) Thomas WASCHER (Austria) Rob WELSH (Canada) William WIJNS (Belgium) Stephan WINDECKER (Switzerland) Uwe ZEYMER (Germany) Printed in Austria by: ROBIDRUCK, A-1200 Vienna 1